Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers
- PMID: 19346218
- PMCID: PMC3207996
- DOI: 10.1136/tc.2008.028993
Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers
Abstract
Background: Non-combustible potential reduced exposure products (PREPs; eg, Star Scientific's Ariva; a variety of other smokeless tobacco products) are marketed to reduce the harm associated with smoking. This marketing occurs despite an absence of objective data concerning the toxicant exposure and effects of these PREPs. Methods used to examine combustible PREPs were adapted to assess the acute effects of non-combustible PREPs for smokers.
Methods: 28 overnight abstinent cigarette smokers (17 men, 14 non-white) each completed seven, Latin-squared ordered, approximately 2.5 h laboratory sessions that differed by product administered: Ariva, Marlboro Snus (Philip Morris, USA), Camel Snus (RJ Reynolds, Winston-Salem, North Carolina, USA), Commit nicotine lozenge (GlaxoSmithKline; 2 mg), own brand cigarettes, Quest cigarettes (Vector Tobacco; delivers very low levels of nicotine) and sham smoking (ie, puffing on an unlit cigarette). In each session, the product was administered twice (separated by 60 min), and plasma nicotine levels, expired air CO and subjective effects were assessed regularly.
Results: Non-combustible products delivered less nicotine than own brand cigarettes, did not expose smokers to CO and failed to suppress tobacco abstinence symptoms as effectively as combustible products.
Conclusions: While decreased toxicant exposure is a potential indicator of harm reduction potential, a failure to suppress abstinence symptoms suggests that currently marketed non-combustible PREPs may not be a viable harm reduction strategy for US smokers. This study demonstrates how clinical laboratory methods can be used to evaluate the short-term effects of non-combustible PREPs for smokers.
Figures

Similar articles
-
Evaluating oral noncombustible potential-reduced exposure products for smokers.Nicotine Tob Res. 2010 Apr;12(4):336-43. doi: 10.1093/ntr/ntq003. Epub 2010 Feb 16. Nicotine Tob Res. 2010. PMID: 20159791 Free PMC article. Clinical Trial.
-
A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects.Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1945-53. doi: 10.1158/1055-9965.EPI-10-0288. Epub 2010 Jul 20. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20647410 Free PMC article.
-
Nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokers.Nicotine Tob Res. 2008 Mar;10(3):417-21. doi: 10.1080/14622200801901880. Nicotine Tob Res. 2008. PMID: 18324559 Free PMC article.
-
[Harm reduction strategy in tobacco control].Epidemiol Prev. 2011 May-Aug;35(3-4 Suppl 1):19-32. Epidemiol Prev. 2011. PMID: 21926451 Review. Italian.
-
Tobacco, nicotine and harm reduction.Drug Alcohol Rev. 2011 Mar;30(2):119-23. doi: 10.1111/j.1465-3362.2010.00264.x. Drug Alcohol Rev. 2011. PMID: 21375611 Review.
Cited by
-
Animal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation.Drug Alcohol Depend. 2015 Feb 1;147:60-7. doi: 10.1016/j.drugalcdep.2014.12.015. Epub 2014 Dec 23. Drug Alcohol Depend. 2015. PMID: 25561387 Free PMC article.
-
E-cigarette use, opinion about harmfulness and addiction among university students in Bratislava, Slovakia.Cent Eur J Public Health. 2022 Jun;30(Supplement):S50-S56. doi: 10.21101/cejph.a7240. Cent Eur J Public Health. 2022. PMID: 35841226
-
Randomized Trial to Compare Smoking Cessation Rates of Snus, With and Without Smokeless Tobacco Health-Related Information, and a Nicotine Lozenge.Nicotine Tob Res. 2019 Jan 1;21(1):88-94. doi: 10.1093/ntr/nty011. Nicotine Tob Res. 2019. PMID: 29373698 Free PMC article. Clinical Trial.
-
Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes.Psychopharmacology (Berl). 2021 Nov;238(11):3325-3334. doi: 10.1007/s00213-021-05948-y. Epub 2021 Aug 25. Psychopharmacology (Berl). 2021. PMID: 34432106 Clinical Trial.
-
Beyond smoking: Risk assessment of nicotine in pouches.Toxicol Rep. 2024 Oct 26;13:101779. doi: 10.1016/j.toxrep.2024.101779. eCollection 2024 Dec. Toxicol Rep. 2024. PMID: 39554607 Free PMC article.
References
-
- Lakier JB. Smoking and cardiovascular disease. Am J Med. 1992;93:8S–12S. - PubMed
-
- Hoffmann D, Hoffmann I. Tobacco consumption and lung cancer. Cancer Treat Res. 1995;72:1–42. - PubMed
-
- Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;4:CD003041. - PubMed
-
- Schroeder SA. What to do with a patient who smokes. JAMA. 2005;294:482–487. - PubMed
-
- Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med. 2008;121:S3–S10. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical